MET and non-small cell lung carcinoma: In solid tumours, in particular, in non‐small cell lung cancer (NSCLC), gastric cancer, and renal carcinoma, c‐MET is frequently mutated or overexpressed, which is associated with poor prognosis and resistance to standard‐of‐care therapies [109].